MESOBLAST LIMITED (MSB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MSB

MSB - MESOBLAST LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -2.26
Index: ASX200 | ASX300 | ALL-ORDS

Mesoblast is a Melbourne-headquartered medical research company investigating stem cell treatments and allogenic cellular medicines. The company was founded and listed in 2004.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.12

30 Apr
2026

-0.100

OPEN

$2.23

-4.50%

HIGH

$2.23

4,181,495

LOW

$2.07

TARGET
$4.45 109.9% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MSB: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 7.9 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-13.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx26.6 M
Book Value Per Share xxxxxxxxxxxxxxx71.2
Net Operating Cash Flow xxxxxxxxxxxxxxx-87.3 M
Net Profit Margin xxxxxxxxxxxxxxx-593.92 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-19.34 %
Return on Invested Capital xxxxxxxxxxxxxxx-16.66 %
Return on Assets xxxxxxxxxxxxxxx-14.34 %
Return on Equity xxxxxxxxxxxxxxx-19.34 %
Return on Total Capital xxxxxxxxxxxxxxx-9.63 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-88.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx87 M
Long Term Debt xxxxxxxxxxxxxxx109 M
Total Debt xxxxxxxxxxxxxxx196 M
Goodwill - Gross xxxxxxxxxxxxxxx205 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx247 M
Price To Book Value xxxxxxxxxxxxxxx2.32

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.1 M
Capex % of Sales xxxxxxxxxxxxxxx4.24 %
Cost of Goods Sold xxxxxxxxxxxxxxx18 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx105 M
Research & Development xxxxxxxxxxxxxxx54 M
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

01/05/2026

1

Speculative Buy

$4.45

109.91%

Based on March quarter results by Mesoblast, Bell Potter highlights improving momentum given March quarter cash burn sharply fell and customer receipts rose strongly on Ryoncil sales.

Revenue guidance for FY26 is unchanged, with continued growth expected, while the business moves toward cash flow positivity.

A key upcoming catalyst, according to the analysts, is the Phase 3 readout for rexlemestrocel in chronic lower back pain, targeting a large US market opportunity.

Bell Potter maintains a Buy (Speculative) rating and target of $4.45.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -7.93 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 10.78 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

14/04/2026

1

Buy

$3.23

52.36%

Canaccord Genuity maintains its Buy rating on Mesoblast with an unchanged $3.23 price target following the biotech's research and development day.

The broker observes management expects to double the current revenue run-rate for its lead product in the medium term.

High uptake is anticipated in the adult population if ongoing trials deliver positive results, the broker reports.

The report concludes regulatory and commercial strategy questions remain for other pipeline programs.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents.
Access Extra Coverage Research History >

MSB STOCK CHART

FNArena News on MSB

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest